Literature DB >> 6352008

Macrophages in cancer metastases and their relevance to metastatic growth.

M E Key.   

Abstract

The dissemination of malignant cells throughout the body to form secondary growths is a highly complex process dependent upon both host and tumor cell properties. One potential defensive system which could influence the outcome of metastasis is the mononuclear phagocyte system. Although macrophages have been observed in essentially all primary and metastatic tumors examined regardless of histologic type or anatomic location, the biological significance of these observations is far from clear. What is clear, however, is that in most cases the effects of macrophages on tumor cells are not sufficient to alter progressive growth. Therefore, the presence of macrophages within metastases does not necessarily signify a protective host defensive response. On the other hand, macrophage-induced regression of established metastases can occur in vivo under certain conditions in which tumor-bearing mice are treated systemically with macrophage-activating agents. When mice bearing metastases are treated with macrophage-activating agents contained within liposomes, metastasis-associated macrophages are activated to the tumoricidal state and the metastatic lesions are simultaneously eradicated. Such a process of macrophage activation may have implications in determining successful approaches to the therapy of disseminated cancer.

Entities:  

Mesh:

Year:  1983        PMID: 6352008     DOI: 10.1007/bf00046906

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  44 in total

1.  Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors.

Authors:  G W Wood; R A Morantz
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

2.  Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages.

Authors:  J B Hibbs
Journal:  J Natl Cancer Inst       Date:  1974-11       Impact factor: 13.506

3.  Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

4.  Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.

Authors:  D P Griswold
Journal:  Cancer Chemother Rep 2       Date:  1972-11

5.  Macrophages in syngeneic animal tumours.

Authors:  R Evans
Journal:  Transplantation       Date:  1972-10       Impact factor: 4.939

6.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

7.  Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages.

Authors:  A Raz; C Bucana; W E Fogler; G Poste; I J Fidler
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

8.  Macrophage accumulation in transplanted tumors is not dependent on host immune responsiveness or presence of tumor-associated rejection antigens.

Authors:  R Evans; D M Eidlen
Journal:  J Reticuloendothel Soc       Date:  1981-11

9.  Macrophage content of metastatic and nonmetastatic rodent neoplasms.

Authors:  J E Talmadge; M Key; I J Fidler
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

10.  Immunohistologic evidence for the role of antibody and macrophages in regression of the murine T1699 mammary adenocarcinoma.

Authors:  M Key; J S Haskill
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

View more
  19 in total

1.  Effects of L2C leukemia on macrophage-mediated responses.

Authors:  D P Collins
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.

Authors:  Aaron P Bloom; Juan M Jimenez-Andrade; Reid N Taylor; Gabriela Castañeda-Corral; Magdalena J Kaczmarska; Katie T Freeman; Kathleen A Coughlin; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh
Journal:  J Pain       Date:  2011-04-15       Impact factor: 5.820

3.  Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain.

Authors:  Juan M Jimenez-Andrade; Aaron P Bloom; James I Stake; William G Mantyh; Reid N Taylor; Katie T Freeman; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

Review 4.  Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

Authors:  J W Kreider; G L Bartlett; B L Butkiewicz
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Neutrophils influence melanoma adhesion and migration under flow conditions.

Authors:  Margaret J Slattery; Cheng Dong
Journal:  Int J Cancer       Date:  2003-09-20       Impact factor: 7.396

6.  Dynamic heterogeneity: isolation of murine tumor cell populations enriched for metastatic variants and quantification of the unstable expression of the phenotype.

Authors:  S D Young; R P Hill
Journal:  Clin Exp Metastasis       Date:  1986 Jul-Sep       Impact factor: 5.150

7.  Defense mechanism and macroscopic tumor growth in lung tissue.

Authors:  K Kayser; W Ebert; N M Merkle; H D Becker
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  Relationship of macrophage content, immunogenicity, and metastatic potential of a murine osteosarcoma of recent origin.

Authors:  J E Talmadge; K A Uithoven; A E Reif
Journal:  Clin Exp Metastasis       Date:  1985 Jan-Mar       Impact factor: 5.150

9.  IFN-treatment of B16-F1 versus B16-F10: relative impact on non-adaptive and T-cell-mediated immune defense in metastatic spread.

Authors:  M Zöller
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

10.  Selective macrophage activation by muramyldipeptide bound to monoclonal antibodies specific for mouse tumor cells.

Authors:  A C Roche; P Bailly; P Midoux; M Monsigny
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.